HIV-Sheltering Platelets From Immunological Non-Responders Induce a Dysfunctional Glycolytic CD4 T-Cell Profile
Overview
Authors
Affiliations
Immunological non-responders (InRs) are HIV-infected individuals in whom the administration of combination antiretroviral therapy (cART), although successful in suppressing viral replication, cannot properly reconstitute patient circulating CD4 T-cell number to immunocompetent levels. The causes for this immunological failure remain elusive, and no therapeutic strategy is available to restore a proper CD4 T-cell immune response in these individuals. We have recently demonstrated that platelets harboring infectious HIV are a hallmark of InR, and we now report on a causal connection between HIV-containing platelets and T-cell dysfunctions. We show here that , platelet-T-cell conjugates are more frequent among CD4 T cells in InRs displaying HIV-containing platelets (<350 CD4 T cells/μl blood for >1 year) as compared with healthy donors or immunological responders (IRs; >350 CD4 T cells/μl). This contact between platelet containing HIV and T cell in the conjugates is not infectious for CD4 T cells, as coculture of platelets from InRs containing HIV with healthy donor CD4 T cells fails to propagate infection to CD4 T cells. In contrast, when macrophages are the target of platelets containing HIV from InRs, macrophages become infected. Differential transcriptomic analyses comparing InR and IR CD4 T cells reveal an upregulation of genes involved in both aerobic and anaerobic glycolysis in CD4 T cells from InR vs. IR individuals. Accordingly, InR platelets containing HIV induce a dysfunctional increase in glycolysis-mediated energy production in CD4 T cells as compared with T cells cocultured with IR platelets devoid of virus. In contrast, macrophage metabolism is not affected by platelet contact. Altogether, this brief report demonstrates a direct causal link between presence of HIV in platelets and T-cell dysfunctions typical of InR, contributing to devise a platelet-targeted therapy for improving immune reconstitution in these individuals.
Lembas A, Zaleski A, Mikula T, Kozlowska J, Wiercinska-Drapalo A Viruses. 2025; 17(2).
PMID: 40006998 PMC: 11860511. DOI: 10.3390/v17020243.
Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai.
Escuder-Rodriguez J, Rodriguez-Alonso A, Jove L, Quiroga M, Alfonsin G, Figueroa A Cell Mol Biol Lett. 2025; 30(1):9.
PMID: 39833727 PMC: 11749156. DOI: 10.1186/s11658-025-00693-y.
Mechanisms of HIV-immunologic non-responses and research trends based on gut microbiota.
Sun X, Xie Z, Wu Z, Song M, Zhang Y, Zhang Z Front Immunol. 2025; 15():1378431.
PMID: 39802299 PMC: 11718445. DOI: 10.3389/fimmu.2024.1378431.
Genetics of ischemic stroke functional outcome.
Carnwath T, Demel S, Prestigiacomo C J Neurol. 2024; 271(5):2345-2369.
PMID: 38502340 PMC: 11055934. DOI: 10.1007/s00415-024-12263-x.
Platelet, a key regulator of innate and adaptive immunity.
Yan C, Wu H, Fang X, He J, Zhu F Front Med (Lausanne). 2023; 10:1074878.
PMID: 36968817 PMC: 10038213. DOI: 10.3389/fmed.2023.1074878.